Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Faron Pharmaceuticals (FARN) Share Price

Price 202.50p on 30-06-2025 at 18:15:12
Change 12.50p 6.58%
Buy 210.00p
Sell 195.00p
Buy / Sell FARN Shares
Last Trade: Sell 4.00 at 197.00p
Day's Volume: 49,560
Last Close: 202.50p
Open: 190.00p
ISIN: FI4000153309
Day's Range 195.00p - 202.50p
52wk Range: 89.00p - 265.00p
Market Capitalisation: £237m
VWAP: 197.49047p
Shares in Issue: 117m

Faron Pharmaceuticals (FARN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 4 197.00p Ordinary
15:38:09 - 30-Jun-25
Buy* 481 205.00p Ordinary
15:20:20 - 30-Jun-25
Sell* 5,000 200.10p Ordinary
15:04:25 - 30-Jun-25
Buy* 788 205.00p Ordinary
15:01:06 - 30-Jun-25
Buy* 750 200.00p Ordinary
14:00:57 - 30-Jun-25
Unknown* 10,000 205.00p Ordinary
14:00:07 - 30-Jun-25
Buy* 477 199.00p Ordinary
12:20:47 - 30-Jun-25
Buy* 2 200.00p SI Trade
11:56:36 - 30-Jun-25
Buy* 440 200.00p Suspected BUY Trade
11:00:24 - 30-Jun-25
Buy* 1,000 197.50p Ordinary
10:27:41 - 30-Jun-25
See more Faron Pharmaceuticals trades

Faron Pharmaceuticals (FARN) Share Price History

Time period:
to
Date Open High Low Close Volume
30th Jun 2025 (Mon) 190.00 202.50 195.00 202.50 49,560
27th Jun 2025 (Fri) 185.00 190.00 185.00 190.00 10,696
26th Jun 2025 (Thu) 192.50 192.50 177.50 185.00 56,749
25th Jun 2025 (Wed) 195.00 195.00 192.50 192.50 18,063
24th Jun 2025 (Tue) 197.50 197.50 195.00 195.00 6,855
23rd Jun 2025 (Mon) 202.50 202.50 197.50 197.50 2,944
20th Jun 2025 (Fri) 202.50 202.50 202.50 202.50 1,356
19th Jun 2025 (Thu) 220.00 220.00 202.50 202.50 36,702
18th Jun 2025 (Wed) 222.50 230.00 215.00 215.00 16,362
17th Jun 2025 (Tue) 222.50 225.00 222.50 222.50 1,725
16th Jun 2025 (Mon) 222.50 235.00 222.50 222.50 5,240
13th Jun 2025 (Fri) 227.50 230.00 230.00 230.00 26,381
12th Jun 2025 (Thu) 227.50 227.50 227.50 227.50 1,882
11th Jun 2025 (Wed) 225.00 235.00 227.50 227.50 3,721
10th Jun 2025 (Tue) 217.50 225.00 217.50 225.00 4,458
9th Jun 2025 (Mon) 215.00 217.50 215.00 217.50 6,142
6th Jun 2025 (Fri) 215.00 215.00 215.00 215.00 5,058
5th Jun 2025 (Thu) 225.00 225.00 212.50 215.00 36,474
4th Jun 2025 (Wed) 230.00 225.00 221.00 225.00 7,456
3rd Jun 2025 (Tue) 250.00 250.00 230.00 230.00 56,966
2nd Jun 2025 (Mon) 262.50 265.00 250.00 252.50 47,656
See more Faron Pharmaceuticals price history

Faron Pharmaceuticals (FARN) Regulatory News

Date Source Headline
3rd Mar 2025 12:05 pm RNS FDA Grants Orphan Drug Designation
28th Feb 2025 12:00 pm RNS Notice of Annual General Meeting
27th Feb 2025 7:30 am RNS Positive EMA Opinion on Orphan Drug Designation
27th Feb 2025 7:15 am RNS Annual Report 2024 published
27th Feb 2025 7:00 am RNS Financial Statement 1 January to 31 December 2024
19th Feb 2025 10:00 am RNS Notice of Financial Statement and Annual Report
14th Feb 2025 12:00 pm RNS Holding(s) in Company
11th Feb 2025 7:30 am RNS Change of Broker
6th Feb 2025 3:00 pm RNS Holding(s) in Company
6th Feb 2025 7:00 am RNS Results of Oversubscribed Placing
See more Faron Pharmaceuticals regulatory news

Faron Pharmaceuticals (FARN) Share News

IN BRIEF: Faron Pharmaceuticals appoints new chief business officer

21st May 2025 12:41

Faron Pharmaceuticals Ltd - Turku, Finland-based developer of cancer immunotherapies - Appoints Ralph Hughes as chief business officer, effective from next Wednesday. Notes Hughes' prior experience as senior vice president at PharmaVentures, and his extensive experience in commercial due diligence, market access and the business development process. Adds that he will be part of the management team and the business development team. "We are delighted to have such an experienced pharmaceutical market access and strategic commercial development expert to join us as the new CBO", says Chief Executive Juho Jalkanen. "Ralph's proven track record in biopharma leadership and his experience align perfectly with our corporate development efforts and strategic growth initiatives." Read More

UK shareholder meetings calendar - next 7 days

14th Mar 2025 14:09

Read More

UK earnings, trading statements calendar - next 7 days

20th Feb 2025 14:16

Read More

Faron Pharmaceuticals raises EUR12 million from oversubscribed placing

6th Feb 2025 11:41

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has raised EUR12 million from an oversubscribed placing ahead of upcoming trial results. Read More

IN BRIEF: Faron Pharmaceuticals shares up as presents data on Bexmab

10th Dec 2024 14:31

Faron Pharmaceuticals PLC on Tuesday - Turku, Finland-based developer of cancer immunotherapies - Presents full analysis of positive phase 2 interim data from Bexmab trial at the annual meeting of the Society of Hematology in San Diego. Faron highlights an overall response rate of 80% in refractory or relapsed HMA failed MDS patient population. HMA stands for hypomethylating agents, while MDS stands for myelodysplastic syndromes. Chief Executive Officer Juho Jalkanen says: "With this compelling evidence, we are well positioned to advance to the full phase 2 efficacy readout and actively pursue further regulatory interactions to navigate and refine the pivotal pathway for BLA filing." Read More

See more Faron Pharmaceuticals news
FTSE 100 Latest
Value8,760.96
Change-37.95

Login to your account

Forgot Password?

Not Registered